Anthem Biosciences Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Cash & Equivalents	3,161	1,839	3,422	3,418	362.82
Short-Term Investments	-	-	4,929	2,691	-
Trading Asset Securities	4,161	4,591	-	-	2,091
Cash & Short-Term Investments	7,323	6,429	8,351	6,109	2,454
Cash Growth	13.90%	-23.01%	36.70%	148.94%	-
Accounts Receivable	4,504	4,904	2,741	3,262	2,546
Other Receivables	95.15	1.96	12.15	73.23	23.47
Receivables	4,599	4,906	2,753	3,335	2,570
Inventory	3,404	2,113	1,294	582.3	350.63
Prepaid Expenses	2.14	31.67	19.43	25.04	17.68
Restricted Cash	-	-	-	-	40.02
Other Current Assets	2,039	1,335	814.18	881.44	725.69
Total Current Assets	17,367	14,816	13,232	10,933	6,158
Property, Plant & Equipment	9,981	8,210	6,039	4,759	3,737
Long-Term Investments	169.28	125.53	61.6	36.96	-
Other Intangible Assets	38.71	62.43	90.89	68.99	64.18
Long-Term Accounts Receivable	31.12	31.08	31.08	31.12	31.28
Long-Term Deferred Tax Assets	179.47	413.95	249.08	159.38	138.7
Other Long-Term Assets	253.87	249.73	370.15	127.81	136.9
Total Assets	28,076	23,981	20,145	16,189	10,338
Accounts Payable	1,101	1,007	719.41	648.41	769.25
Accrued Expenses	252.29	308.02	249.82	245.63	267.01
Short-Term Debt	429.53	817.96	87.46	274.93	213.84
Current Portion of Long-Term Debt	189.74	390.71	201.3	11.5	577.92
Current Portion of Leases	15.06	16.85	3.22	21.22	22.44
Current Income Taxes Payable	230.27	64.11	58.83	193.89	256.99
Current Unearned Revenue	-	-	3.85	-	8.23
Other Current Liabilities	1,045	781.21	314.81	866.29	734.14
Total Current Liabilities	3,262	3,386	1,639	2,262	2,850
Long-Term Debt	470.28	1,117	961.88	245.8	174.64
Long-Term Leases	28.56	43.06	7.64	24.39	34.88
Long-Term Unearned Revenue	9.35	11.69	14.18	16.64	19.02
Other Long-Term Liabilities	162.81	137.21	81.89	57.99	197.33
Total Liabilities	3,977	4,735	2,738	2,639	3,324
Common Stock	1,118	1,118	1,141	87.76	84.85
Additional Paid-In Capital	1,252	1,252	2,719	2,700	228.1
Retained Earnings	21,392	16,879	13,570	10,726	6,658
Comprehensive Income & Other	336.79	-2.72	-23.05	35.82	44.15
Shareholders' Equity	24,099	19,247	17,407	13,550	7,015
Total Liabilities & Equity	28,076	23,981	20,145	16,189	10,338
Total Debt	1,133	2,385	1,262	577.84	1,024
Net Cash (Debt)	6,190	4,044	7,090	5,531	1,430
Net Cash Growth	53.05%	-42.96%	28.17%	286.71%	-
Net Cash Per Share	11.02	7.13	12.43	9.70	2.62
Filing Date Shares Outstanding	561.61	559.08	570.49	570.46	546.78
Total Common Shares Outstanding	559.08	559.08	570.49	570.46	546.78
Working Capital	14,105	11,429	11,593	8,671	3,308
Book Value Per Share	43.10	34.43	30.51	23.75	12.83
Tangible Book Value	24,060	19,184	17,316	13,481	6,950
Tangible Book Value Per Share	43.04	34.31	30.35	23.63	12.71
Land	836.13	836.13	836.13	836.13	836.13
Buildings	3,239	2,012	1,579	1,304	1,304
Machinery	8,595	6,761	6,137	4,632	4,439
Construction In Progress	2,969	3,447	1,641	1,538	186.8

Source: S&P Global Market Intelligence. Standard template. Financial Sources.